Cancer inhalation therapy: a novel platform for cancer vaccine utilizing the mucosal immune system in the airways

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670579
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: The University of Tokyo (2015); Kyoto University (2014)
• Principal Investigator: Sato Masaaki 東京大学, 医学部附属病院, 講師 (00623109)
• Co-Investigator(Kenkyū-buntansha): Menju Toshi 京都大学, 医学(系)研究科(研究院), 助教 (30527081) ; Aoyama Akihiro 京都大学, 医学(系)研究科(研究院), 助教 (60379047)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 癌免疫 / 癌ワクチン / 肺癌 / 制御性T細胞

Outline of Final Research Achievements

The purpose of the present study was to establish a "cancer vaccine inhalation therapy" as a novel platform of cancer immunotherapy. Particularly, a novel animal model implanting a B6-mice-derived lung cancer cell line (Liewis cells) into the lung of immunocompetent wild-type B6 mice enabled observation of the hosts' immune response to cancer cells in vivo. Administration of dead cancer cells in combination with adjuvant BCG resulted in attenuation of cancer-relate weight loss and improvement in survival. This effect was further enhanced by combining with systemic administration of low-dose cyclophosphamide, which reduces regulatory T cells in a relatively selective manner. The manuscript describing the outcomes of this study is under submission for a medical journal.

Free Research Field

癌免疫